Fig 3.

microPET/CT scan and standardized-uptake value (SUV) analysis as a means of visualizing insulinoma responsiveness to monthly subcutaneous injections of pasireotide (SOM230) (160mg/Kg/month [64mg/ml]) or PBS over four months. (A) microPET/CT scan demonstrating the presence of increased metabolism/excretion by normal organs (brain, heart, kidneys, and bladder) and an insulinoma prior to treatment with SOM230 (arrow). (B) microPET/CT scan demonstrating the presence of increased metabolism/excretion by normal organs with decreased activity in the insulinoma following four months treatment with SOM230. (C) SUV measurements for each mouse represented as a percent change in activity beginning from pre-treatment until either death or four months treatment with either SOM230 or PBS (100 × [SUV_final - SUV_{pre-treatment}]/SUV_{pre-treatment})

*Mice M2, M3, and M4 of the PBS group expired prior to completion of the study (days 68, 74, and 82, respectively)